"Glioblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Descriptor ID |
D005909
|
| MeSH Number(s) |
C04.557.465.625.600.380.080.335 C04.557.470.670.380.080.335 C04.557.580.625.600.380.080.335
|
| Concept/Terms |
Glioblastoma- Glioblastoma
- Glioblastomas
- Astrocytoma, Grade IV
- Astrocytomas, Grade IV
- Grade IV Astrocytoma
- Grade IV Astrocytomas
Giant Cell Glioblastoma- Giant Cell Glioblastoma
- Giant Cell Glioblastomas
- Glioblastoma, Giant Cell
- Glioblastomas, Giant Cell
|
Below are MeSH descriptors whose meaning is more general than "Glioblastoma".
Below are MeSH descriptors whose meaning is more specific than "Glioblastoma".
This graph shows the total number of publications written about "Glioblastoma" by people in this website by year, and whether "Glioblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 2 | 0 | 2 |
| 2014 | 4 | 0 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 1 | 4 |
| 2017 | 41 | 3 | 44 |
| 2018 | 43 | 6 | 49 |
| 2019 | 13 | 0 | 13 |
| 2020 | 0 | 1 | 1 |
| 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Glioblastoma" by people in Profiles.
-
Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19. Brief Bioinform. 2021 09 02; 22(5).
-
Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events. J Neurol. 2022 Feb; 269(2):616-618.
-
Evidence for residual SARS-CoV-2 in glioblastoma tissue of a convalescent patient. Neuroreport. 2021 06 09; 32(9):771-775.
-
The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic. JAMA Oncol. 2021 05 01; 7(5):675-676.
-
From glioblastoma to COVID-19 – role of oxysterols in the human organism Postepy Biochem. 2021 06 30; 67(2):163-171.
-
Susceptibility of neuroblastoma and glioblastoma cell lines to SARS-CoV-2 infection. Brain Res. 2021 05 01; 1758:147344.
-
Approaching glioblastoma during COVID-19 pandemic: current recommendations and considerations in Brazil. Arq Neuropsiquiatr. 2021 02; 79(2):167-172.
-
Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner. Signal Transduct Target Ther. 2020 11 13; 5(1):266.
-
Overview of prognostic factors in adult gliomas. Ann Palliat Med. 2021 Jan; 10(1):863-874.
-
Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas. Curr Radiopharm. 2020; 13(2):94-98.